- Conditions
- Early Breast Cancer
- Interventions
- Ribociclib, Endocrine Therapy (ET)
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 5,101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2030
- U.S. locations
- 73
- States / cities
- Birmingham, Alabama • Goodyear, Arizona • Jonesboro, Arkansas + 68 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1657–1680
of 12,241
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hypertension
- Interventions
- Aliskiren
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007
- U.S. locations
- 19
- States / cities
- Orangevale, California • Brooklyn Center, Minnesota • Butte, Montana + 16 more
- Conditions
- Multiple Myeloma in Relapse, Multiple Myeloma
- Interventions
- Ulocuplumab, Lenalidomide, Bortezomib, Dexamethasone
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Multiple Myeloma
- Interventions
- Iberdomide, Elotuzumab, Dexamethasone
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Multiple Sclerosis
- Interventions
- Positive Psychology
- Behavioral
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Seasonal Allergic Rhinitis
- Interventions
- ACT-129968, Placebo, Cetirizine
- Drug
- Lead sponsor
- Idorsia Pharmaceuticals Ltd.
- Industry
- Eligibility
- 12 Years to 76 Years
- Enrollment
- 630 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 7
- States / cities
- Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 1 more
- Conditions
- Multiple Sclerosis
- Interventions
- Hematopoietic Stem Cell Therapy, Standard treatment with a conventional drug
- Procedure · Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2019
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Multiple Myeloma, Relapse Multiple Myeloma, Refractory Multiple Myeloma
- Interventions
- Elranatamab, GM-CSF, DC/MM Fusion Vaccine
- Drug · Biological
- Lead sponsor
- David Avigan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Multiple Sclerosis, Optic Neuritis, Transverse Myelitis, Acute Brainstem/Cerebellar Syndrome
- Interventions
- interferon beta 1a 30 ug IM once weekly
- Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2009
- U.S. locations
- 20
- States / cities
- Derby, Connecticut • Tampa, Florida • Atlanta, Georgia + 16 more
- Conditions
- Schizophrenia
- Interventions
- Luvadaxistat, Matching Placebo
- Drug
- Lead sponsor
- Neurocrine Biosciences
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Gaithersburg, Maryland
- Conditions
- Multiple Sclerosis
- Interventions
- Blood sample collection for coagulation profile
- Diagnostic Test
- Lead sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
- Other
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Prostate Cancer
- Interventions
- 99mTc-MIP-1404
- Drug
- Lead sponsor
- Molecular Insight Pharmaceuticals, Inc.
- Industry
- Eligibility
- 21 Years and older · Male only
- Enrollment
- 6 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2012
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Children and Adolescent With Type 2 Diabetes
- Interventions
- Exenatide Once Weekly, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2021
- U.S. locations
- 16
- States / cities
- Los Angeles, California • New Haven, Connecticut • Iowa City, Iowa + 13 more
- Conditions
- Multiple Myeloma
- Interventions
- Lenalidomide, Bortezomib, Dexamethasone
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 6
- States / cities
- Baltimore, Maryland • Boston, Massachusetts • Danvers, Massachusetts
- Conditions
- Older Adults, Multiple Sclerosis, Cognitive Impairment, Walking Impairment
- Interventions
- Aerobic and Resistance Exercise Program (GEMS program), Flexibility and Stretching Program (FLEX-MS program)
- Behavioral
- Lead sponsor
- University of Illinois Chicago
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Cardiac Arrhythmia
- Interventions
- Arrhythmia Management System (AMS)
- Device
- Lead sponsor
- Zoll Medical Corporation
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 585 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 20
- States / cities
- Bakersfield, California • Long Beach, California • Los Angeles, California + 15 more
- Conditions
- Down Syndrome, Cognitive Dysfunction
- Interventions
- Aricept (donepezil hydrochloride), Placebo
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 11 Years to 17 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 2
- States / cities
- San Antonio, Texas • Herndon, Virginia
- Conditions
- Training Study, Multiple Sclerosis, Blood Flow Restriction
- Interventions
- Blood Flow Restriction, Standard of Care
- Other
- Lead sponsor
- University of Central Florida
- Other
- Eligibility
- 18 Years to 55 Years · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Multiple Sclerosis, Mild Cognitive Impairment, Cancer
- Interventions
- CT-100 DiNaMo, Care-as-Usual
- Other
- Lead sponsor
- Click Therapeutics, Inc.
- Industry
- Eligibility
- 22 Years to 75 Years
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Multiple Sclerosis
- Interventions
- Exercise program for people with MS
- Behavioral
- Lead sponsor
- Shepherd Center, Atlanta GA
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 379 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Denver, Colorado • Athens, Georgia + 5 more
- Conditions
- Prader-Willi Syndrome
- Interventions
- DCCR
- Drug
- Lead sponsor
- Soleno Therapeutics, Inc.
- Industry
- Eligibility
- 4 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 17
- States / cities
- Orange, California • Palo Alto, California • San Diego, California + 14 more
- Conditions
- Multiple Myeloma
- Interventions
- Denosumab Q4W
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 7
- States / cities
- Atlanta, Georgia • Boston, Massachusetts • Danvers, Massachusetts + 3 more
- Conditions
- Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Gene Mutations, Acute Myeloid Leukemia With Inv(3) (q21.3;q26.2); GATA2, MECOM, Acute Myeloid Leukemia With t(6;9) (p23;q34.1); DEK-NUP214, Aplastic Anemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Follicular Lymphoma, Hodgkin Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloid Leukemia, Non-Hodgkin Lymphoma, Plasma Cell Myeloma, Polycythemia Vera, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia
- Interventions
- Fludarabine phosphate, Busulfan, Total-Body Irradiation, Therapeutic Allogeneic Lymphocytes, Cyclophosphamide, Allogeneic Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Tacrolimus, Mycophenolate Mofetil, Laboratory Biomarker Analysis
- Drug · Radiation · Biological + 2 more
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Other
- Eligibility
- Not listed
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2022
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Multiple Myeloma
- Interventions
- MGTA-145, Plerixafor
- Drug
- Lead sponsor
- Surbhi Sidana, MD
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Stanford, California